Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS

Neurology

Volumn 55, Issue 7, 2000, Pages 928-934

  Huang, Wen Xi ^a   Huang, P ^a   Gomes, A ^a   Hillert, J ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Biosciences at Novum   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MESSENGER RNA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 0034633769     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.7.928     Document Type: Article

References (39)

1. Apoptosis and autoimmune disease
2. The role of Fas in autoimmune diabetes
3. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/ p55TNF receptor signaling in the central nervous system of transgenic mice: Models for multiple sclerosis with primary oligodendrogliopathy
4. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis
5. Apoptosis: Molecular regulation of cell death
6. Fas ligand mediates activation-induced cell death in human T lymphocytes
7. The biology of the immune system
8. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
9. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
10. Tumour necrosis factor and lymphotoxin: Molecular aspects and role in tissue-specific autoimmunity
11. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
12. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis
13. The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus
14. Multiple sclerosis: Fas signaling in oligodendrocyte cell death
15. Multiple sclerosis: Expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque
16. Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis
17. Cell death and birth in multiple sclerosis brain
18. Increased Fas antigen on T cells in multiple sclerosis
19. CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2
20. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis
21. Serum sAPO-1/Fas levels in multiple sclerosis
22. Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients
23. The pattern of production of cytokine mRNAs is markedly altered at the onset of multiple sclerosis
24. Expression of costimulatory molecules and cytokines in CSF and peripheral blood mononuclear cells from multiple sclerosis patients
25. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity
26. Cytokine analysis in multiple sclerosis by competitive RT-PCR a decreased expression of IL-10 and an increased expression of TNF-α in chronic progression
27. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
28. Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction
29. A rapid and versatile method to synthesize internal standards for competitive PCR
30. The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis
31. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis
32. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis
33. The receptor for the cytotoxic ligand TRAIL
34. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
35. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
36. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
37. TRAIL/Apo-2-ligand-induced apoptosis in human T cells
38. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells
39. TNF neutralization in MS